Compare Costco Wholesale Corporation (COST) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Costco (COST) trades at $947.92, up 0.6% with strong technical momentum. The stock shows robust fundamentals with revenue growth from $275.24B in 2025 to projected $303.2B in 2026 and improving net margins. Recent March sales surged 11.3% year-over-year, while analyst consensus remains strongly bullish with 66% buy ratings and a $1,100 price target. Technical indicators show bullish moving averages but overbought RSI levels near resistance at $954.

Outlook remains positive given membership fee increases and expansion potential, though high valuation multiples (P/E 45.66) pose risk if growth slows. Key risks include competitive pressures and economic sensitivity. Institutional accumulation continues with multiple advisors increasing positions in Q4 2025, supporting the bullish thesis.

INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.

Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.